1887

Chapter 25 : Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818364/9781555810672_Chap25-1.gif /docserver/preview/fulltext/10.1128/9781555818364/9781555810672_Chap25-2.gif

Abstract:

The experimental evidence to date indicates that the level of serum vibriocidal antibodies is correlated with the resistance of humans to cholera. This chapter proposes that a critical level of serum vibriocidal antibodies alone can prevent cholera, and describes a mechanism by which this may occur. On the basis of this hypothesis, vaccines have been designed to elicit antibodies, especially of the immunoglobulin G (IgG) class, to the lipopolysaccharide (LPS) of . The strongest evidence that serum vibriocidal antibodies may confer protective immunity comes from clinical studies of cholera vaccines composed of inactivated O1 (cellular vaccines). The authors have reconsidered the data that suggest that serum-neutralizing antibodies to cholera toxin (CT) (antitoxin) do not confer protection against cholera. As has been observed for many viral and bacterial diseases, serum antibodies are effective preventive but not therapeutic agents. This principle is probably also true for cholera. Clinical, epidemiologic, and experimental data support the hypothesis that serum vibriocidal antibodies confer protective immunity to cholera. The authors developed conjugate vaccines composed of the detoxified LPS of O1 serotype Inaba bound to CT that were designed to elicit protective levels of vibriocidal antibodies, especially in infants as part of their routine immunization. Cholera conjugate vaccines have the potential to elicit protection in infants when injected along with diphtheria-typhoid-pertussis vaccine and the type b conjugate as part of routine immunization.

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25

Key Concept Ranking

Bacterial Vaccines
0.9109094
Small Intestine
0.68409437
Bacterial Diseases
0.60596937
Conjugate Vaccines
0.5937411
0.9109094
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

13C NMR spectra () of V. cholerae O1 LPS, serotypes Inaba and Ogawa , recorded on a JEOL GSX-500 spectrometer. Approximately 10 mg of each LPS was dissolved in 0.5 ml of D2O and 1 µl of trimethylamine. The spectra were recorded at ambient probe temperature (ca. 20°C), and 40,000 free induction decay signals were averaged. Chemical shifts are relative to external sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4.

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

31P NMR spectra () of V. cholerae O1 LPS serotypes Inaba and Ogawa , recorded on a JEOL GSX-500 spectrometer. Approximately 10 mg of each LPS was dissolved in 0.5 ml of D20 and 1 µ1 of trimethylamine and recorded at ambient probe temperature (20°C).

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

DeA-LPS was thiolated with SPDP and mixed with N-pyridyl dithio-derivatized protein. Cyanogen-derivatized DeA-LPS was linked with adipic acid dihydrazide. The hydrazide-derivatized polysaccharide was then linked to proteins in the presence of carbodiimide.

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818364.chap25
1. Ahmed, A.,, A. K. Bhattacharjee,, and W. H. Mosley. 1970. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. J. Immunol. 105:431441.
2. Anderson, P. W.,, M. E. Pichichero,, R. A. Insel,, R. Betts,, R. Eby,, and D. H. Smith. 1986. Vaccines consisting of periodate-cleaved oligosaccharide from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J. Immunol. 137:11811186.
3. Azurin, J. C.,, A. Cruz,, T. P. Persigan,, M. Alvero,, T. Camena,, R. Suplido,, L. Ledesma,, and C. A. Gomez. 1967. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull. W.H.O. 37:703727.
4. Batty, I.,, and J. J. Bullen. 1961. The permeability of the sheep and rabbit intestinal wall to antitoxin present in the circulation. J. Pathol. Bacteriol. 81:44758.
5. Baudry, B.,, A. Fasano,, J. Ketley,, and J. B. Kaper. 1992. Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect. Immun. 60:428434.
6. Benenson, A. S., 1976. Review of experience with whole-cell and somatic antigen vaccines, p. 228242. In H. Fukimi, and Y. Zinnaka (ed.), Proceedings of the 12th Joint Conference of U. S. -Japan Cooperative Medical Science Program, Cholera Panel. National Institute of Health, Tokyo.
7. Benenson, A. S.,, P. R. Joseph,, and R. O. Oseasohn. 1968. Cholera vaccine field trials in East Pakistan. Bull. W.H.O. 38:347357.
8. Black, R. E.,, M. M. Levine,, M. L. Clements,, C. R. Young,, A.-M. Svennerholm,, and J. Holmgren. 1987. Protective efficacy in humans of killed whole- Vibrio oral cholera vaccine with and without B subunit of cholera toxin. Infect. Immun. 55:11161120.
9. Bottiger, M. 1984. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating virus. Rev. Infect. Dis. 6(Suppl. 2):S548S551.
10. Bottiger, M.,, and E. Herrstrom. 1992. Isolation of polioviruses from sewage and their characteristics: experience over two decades in Sweden. Scand. J. Infect. Dis. 24:151155.
11. Brade, H. 1985. Occurrence of 2-keto-deoxyoc-tonic acid 5-phosphate in lipopolysaccharides of Vibrio cholerae Ogawa and Inaba. J. Bacteriol. 161:795798.
12. Burnette, W. N.,, V. L. Mar,, B. W. Platler,, J. D. Schotterbeck,, M. D. McGinley,, K. S. Stoney,, M. F. Rohde,, and H. R. Kaslow. 1991. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect. Immun. 59:42664270.
13. Cash, R. A.,, S. I. Music,, J. P. Libonati,, J. P. Craig,, N. E Pierce,, and R. B. Hornick. 1974. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J. Infect. Dis. 130:325333.
14. Centers for Disease Control. 1988. Cholera vaccine. Morbid. Mortal. Weekly Rep. 37:617624.
15. Chu, C. Y.,, B. Liu,, D. Watson,, S. C. Szu,, D. Bryla,, J. Shiloach,, R. Schneerson,, and J. B. Robbins. 1991. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect. Immun. 59:44504458.
16. Clemens, J. D.,, and R. A. Finkelstein. 1978. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect. Immun. 22:709713.
17. Clemens, J. D.,, D. A. Sack,, J. Chakraborty,, M. R. Rao,, F. Ahmed,, J. R. Harris,, F. van Loon,, M. R. Khan,, Md. Yunis,, S. Huda,, B. A. Kay,, A.-M. Svennerholm,, and J. Holmgren. 1990. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 8:469472.
18. Clemens, J. D.,, D. A. Sack,, J. R. Harris,, J. Chakraborty,, P. K. Neogy,, B. Stanton,, N. Huda,, M. U. Khan,, B. A. Kay,, M. R. Khan,, M. Anaruzzaman,, M. Yunis,, M. Rao,, A.-M. Svennerholm,, and J. Holmgren. 1988. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterogenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:372377.
19. Clemens, J. D.,, D. A. Sack,, J. R. Harris,, F. van Loon,, J. Chakraborty,, F. Ahmed,, M. R. Rao,, M. R. Khan,, M. Yunis,, N. Huda,, B. F. Stanton,, B. Kay,, S. Walter,, R. Eckels,, A.-M. Svennerholm,, and J. Holmgren. 1990. Field trial of oral cholera vaccines in Bangladesh: results from three year-follow-up. Lancet 335:270273.
20. Clemens, J. D.,, F. van Loon,, D. A. Sack,, J. Chakraborty,, M. R. Rao,, F. Ahmed,, J. R. Harris,, M. R. Khan,, M. Yunis,, S. Huda,, B. A. Kay,, A.-M. Svennerholm,, and J. Holmgren. 1991. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163:12351242.
21. Code of Federal Regulations. 1990. C, 610.13(b).
22. Dafni, Z.,, and J. B. Robbins. 1976. Purification of heat-labile enterotoxin from Escherichia coli 078:H11 by affinity chromatography with antiserum to Vibrio cholerae toxin, J. Infect. Dis. 133:S138S141.
23. DeMaria, A.,, M. A. Johns,, H. Berbeerich,, and W. R. McCabe. 1988. Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J. Infect. Dis. 158:301311.
24. Eddie, D. S.,, M. L. Schulkind,, and J. B. Rob-bins. 1971. The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium O antibodies from rabbit intestinal fluid and colostrum. J. Immunol. 106:181190.
25. Elson, C. O.,, and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:27362741.
26. Enteric Diseases Branch. 1991. Update: cholera—Western Hemisphere 1991. Morbid. Mortal. Weekly Rep. 40:860.
27. Fattom, A.,, C. Lue,, S. C. Szu,, J. Mestecky,, G. Schiffman,, D. Bryla,, W. F. Vann,, D. Watson,, L. M. Kimzey,, J. B. Robbins,, and R. Schneerson. 1990. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect. Immun. 58:23092312.
28. Feeley, J. C.,, and E. J. Gangarosa,. 1980. Field trials of cholera vaccine, p. 204210. In O. Ouchterlony, and J. Holmgren (ed.), Cholera and Related Diarrheas. 43rd Nobel Symposium. Karger, Basel.
29. Feeley, J. C.,, and M. Pittman. 1962. A mouse protection test for assay of cholera vaccine, p. 9294. In SEATO Conference on Cholera. Publishing Co., Bangkok, Thailand.
30. Finkelstein, R. A. Personal communication.
31. Finkelstein, R. A. 1962. Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of V. cholerae antigens. J. Immunol. 89:264271.
32. Finkelstein, R. A. 1973. Cholera. Crit. Rev. Microbiol. 2:553623.
33. Finkelstein, R. A., 1984. Cholera, p. 107136. In R. Germainer (ed.), Bacterial Vaccines. Academic Press, Inc., New York.
34. Finkelstein, R. A.,, C. J. Powell, Jr.,, J. C. Woodrow,, and J. R. Krevans. 1965. Serological responses in man to a single small dose of cholera vaccine with special reference to the lack of influence of ABO blood groups on natural antibody or immunological responsiveness. Bull. Johns Hopkins Hosp. 116:152160.
35. Glass, R. I.,, I. Huq,, A. Arma,, and M. Yunis. 1980. Emergence of multiple antibiotic resistant Vibrio cholerae in Bangladesh. J. Infect. Dis. 142:929942.
36. Glass, R. I.,, A.-M. Svennerholm,, M. R. Khan,, S. Huda,, M. I. Huq,, and J. Holmgren. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236242.
37. Gupta, R. K.,, S. C. Szu,, R. A. Finkelstein,, and J. B. Robbins. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:32013208.
38. Hardy, A. V.,, T. DeCapito,, and S. P. Halbert. 1948. Studies of the acute diarrheal diseases. XIX. Immunization in Shigellosis. Public Health. Rep. 63:685688.
39. Hisatsune, K.,, Y. Haishima,, T. Iguchi,, and S. Kondo. 1990. Lipopolysaccharides of non-cholera vibrios possessing common antigen factor to O1 Vibrio cholera. Adv. Exp. Med. Biol. 256:189197.
40. Hochstein, H. D., 1990. Role of the FDA in regulating the Limulus amoebocyte lysate test, p. 3849. In R. B. Prior (ed.), Clinical Applications of the Limulus Amoebocyte Lysate Test. CRC Press, Boca Raton, Fla.
41. Holmgren, J.,, and A.-M. Svennerholm. 1977. Mechanism of disease and immunity in cholera: a review. J. Infect. Dis. 136:S105S108.
42. Jertborn, M.,, A.-M. Svennerholm,, and J. Holmgren. 1986. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. Infect. Immun. 24:203209.
43. Joo, I.,, Z. Csizer,, and V. P. Juhasz. 1972. Immune response to plain and adsorbed cholera vaccines. Prog. Immunobiol. Stand. 5:350354.
44. Kabir, S. 1987. Preparation and immunogenicity of a bivalent cell-surface protein-polysaccharide conjugate of Vibrio cholerae. J. Med. Microbiol. 23:918.
45. Kaca, W.,, L. Brade,, E. T. Rietschel,, and H. Brade. 1986. The effect of removal of D-fructose on the antigenicity of the lipopolysaccharide from a rough mutant of Vibrio cholerae Ogawa. Carbohydr. Res. 149:293298.
46. Kaper, J. B.,, and M. M. Levine. 1990. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res. Microbiol. 141:901906.
47. Kaur, J.,, W. Burrows,, and M. A. Furlong. 1971. Immunity to cholera: antibody response in the lower ileum of the rabbit. J. Infect. Dis. 124:359366.
48. Kazemi, M.,, and R. A. Finkelstein. 1990. Study of epitopes of cholera enterotoxin-related enterotoxins by checkerboard immunoblotting. Infect. Immun. 58:23522360.
49. Kenne, L.,, B. Lindberg,, P. Unger,, B. Gustafsson,, and T. Holme. 1982. Structural studies of the Vibrio cholerae O-antigen. Carbohydr. Res. 100:341349.
50. Landy, M.,, S. Gaines,, J. R. Seal,, and J. E. Whiteside. 1954. Antibody responses of man to three types of antityphoid immunizing agents: heat-phenol fluid vaccine, acetone-dehydrated vaccine and isolated Vi antigens. Am. J. Public Health 44:15721579.
51. Levine, M. M. Personal communication.
52. Levine, M. M., 1980. Immunity to cholera as evaluated in volunteers, p. 195203. In O. Ouchterlony, and J. Holmgren (ed.), Cholera and Related Diarrheas. 43rd Nobel Symposium. Karger, Basel.
53. Levine, M. M. 1991. South America: the return of cholera. Lancet i:4546.
54. Levine, M. M.,, R. E. Black,, M. L. Clements,, L. Cisneros,, D. R. Nalin,, and C. R. Young. 1981. The quality and duration of infection-derived immunity to cholera. J. Infect. Dis. 143:818820.
55. Levine, M. M.,, R. E. Black,, M. L. Clements,, C. Lanata,, S. Sears,, T. Honda,, C. R. Young,, and R. A. Finkelstein. 1984. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun. 43:515522.
56. Lindberg, B., 1993. Vibrio cholerae polysaccharide studies, p. 6465. In P. J. Garegg, and A. A. Lindberg (ed), Carbohydrate Antigens. American Chemical Society, Washington, D.C.
57. Lugowski, C.,, and E. Romanowska. 1974. Chemical studies on Shigella sonnei lipid A. Eur. J. Biochem. 48:319324.
58. Manning, P. A.,, M. W. Heuzenroeder,, J. Yeadon,, D. I. Leavesley,, P. R. Reeves,, and D. Rowley. 1986. Molecular cloning and expression in Escherichia coli K-12 of the O antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae O1 lipopolysaccharides and their potential for vaccine development. Infect. Immun. 53:272277.
59. Marchlewicz, B. A.,, and, R. A. Finkelstein. 1983. Immunological differences among the cholera/coli family of enterotoxins. Diagn. Microbiol. Infec. 1:129138.
60. McCormack, W. M.,, A. S. M. Rahman,, A. K. M. Chowdhury,, W. H. Mosley,, and R. A. Philips. 1969. 1965-67 cholera vaccine trial in rural East Pakistan. 3. The lack of effect of prior vaccination or circulating antibody on the severity of clinical cholera. Bull. W.H.O. 60:199204.
61. McCormack, W. M. K.,, J. Chakraborty,, A. S. M. M. Rahman,, and W. H. Mosley. 1969. Vibriocidal antibody in clinical cholera. J. Infect. Dis. 120:192201.
62. McGroarty, E. J.,, and M. Rivera. 1990. Growth dependent alterations in production of serotype specific and common antigen lipopolysaccharides in Pseudomonas aeruginosa PAO1. Infect. Immun. 58:10301037.
63. Meade, B. D.,, P. D. Kind,, J. B. Ewell,, P. McGrath,, and C. R. Manclark. 1984. In-vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect. Immun. 45:718725.
64. Merritt, C. B.,, and R. B. Sack. 1970. Sensitivity of agglutinating and vibriocidal antibodies to 2-mercaptoethanol in human cholera. J. Infect. Dis. 121:S25S30.
65. Migasena, S.,, P. Pitisuttitham,, B. Pray-urahong,, P. Suntharasamal,, W. Supanaranond,, V. Desakorn,, U. Vongsthongsri,, B. Tall,, J. Ketley,, G. Losonsky,, S. Cryz, Jr.,, J. Kaper,, and M. M. Levine. 1989. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect. Immun. 57:32613264.
66. Mosley, W. H. 1969. The role of immunity in cholera. A review of epidemiological and serological studies. Tex. Rep. Biol. Med. 27:S227S241.
67. Mosley, W. H.,, S. Ahmed,, A. S. Benenson,, and A. Ahmed. 1968. The relationship of vibriocidal antibody titre to susceptibility of cholera in family contacts of cholera patients. Bull. W.H.O. 38:777785.
68. Mosley, W. H.,, K. J. Bart,, and A. Sommer. 1972. An epidemiological assessment of cholera. 1. Control programs in rural East Pakistan. Int. J. Epidemiol. 1:511.
69. Mosley, W. H.,, J. C. Feeley,, and M. Pitt man. 1968. The interrelationships of serological responses in humans, and the active mouse protection test to cholera vaccine effectiveness. Ser. Im-munobiol. Stand. 15:185196.
70. Mosley, W. H.,, W. M. McCormack,, A. Ahmed,, A. K. M. Alauddan Chowdhury,, and R. K. Barui. 1969. Report of the 1966-1967 cholera vaccine field trial in rural East Pakistan. Bull. W.H.O. 40:187197.
71. Mosley, W. H.,, W. E. Woodward,, K. M. A. Aziz,, A. S. M. Mizanur Rahman,, A. K. M. Chowdhury,, A. Ahmed,, and J. C. Feeley. 1970. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 121:S1S9.
72. Nalin, D. R.,, R. J. Levine,, M. M. Levine,, D. Hoover,, E. Bergquist,, J. McLaughlin,, J. Libonati,, J. Alam,, and R. B. Hornick. 1978. Cholera, non-vibrio cholera, and stomach acid. Lancet ii:856859.
73. Neoh, S. H.,, and D. Rowley. 1970. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis. 121:505513.
74. Neoh, S. H.,, and D. Rowley. 1972. Protection of infant mice against cholera by antibodies to three antigens of Vibrio cholera. J. Infect. Dis. 126:4147.
75. Noriki, H., 1977. Evaluation of toxoid field trial in the Philippines, p. 302310. In H. Fukimi, and Y. Zinnaka (ed.), Proceedings of the 12th Joint Conference U.S.-Japan Cooperative Medical Science Program. National Institute of Health, Tokyo.
76. Ohtomo, N., 1977. Safety and potency tests of cholera toxoid Lot II in animals and volunteers, p. 286296. H. Fukimi, and Y. Zinnaka (ed.), Proceedings of the 12th Joint Conference U.S.-Japan Cooperative Medical Sciences Program. National Institute of Health, Tokyo.
77. Orskov, F.,, and I. Orskov. 1978. Serotyping of enterobacteriacae, with special emphasis on K antigen determination. Methods Microbiol. 11:177.
78. Pappenheimer, A. M., Jr. 1983. Studies on the molecular epidemiology of diphtheria. Lancet ii:293295.
79. Parsot, C.,, E. Taxman,, and J. J. Mekalanos. 1991. ToxR regulated the production of lipoproteins and the expression of serum resistance in Vibrio cholerae. Proc. Natl. Acad. Sci. USA 88:16411645.
80. Peterson, J. W. 1979. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect. Immun. 26:528533.
81. Philippines Cholera Committee. 1973. A controlled field trial on the effectiveness of the intradermal and subcutaneous administration of cholera vaccine in the Philippines. Bull. W.H.O. 49:389394.
82. Pierce, N. F.,, W. C. Cray, Jr.,, J. B. Kaper,, and J. J. Mekalanos. 1988. Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae O1 in rabbits. Infect. Immun. 56:142148.
83. Pierce, N. F.,, E. A. Kaniecki,, and R. S. Northrup. 1972. Protection against experimental cholera by antitoxin. J. Infect. Dis. 126:606616.
84. Pierce, N. F.,, and H. Y. Reynolds. 1974. Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization.J. Immunol. 113:10171023.
85. Rappaport, R. S.,, and G. Bonde. 1981. Development of a vaccine against experimental cholera and Escherichia coli and diarrheal disease. Infect. Immun. 32:534542.
86. Raziuddin, S. 1978. Toxic and immunologic properties of the lipopolysaccharides (O-antigens) from Vibrio EL-TOR. Immunochemistry 15:611614.
87. Redmond, J. W. 1979. The structure of the O-an-tigenic side chain of the lipopolysaccharide 22 of Vibrio cholerae 569B (Inaba). Biochim. Biophys. Acta 584:346352.
88. Redmond, J. W.,, and M. J. Korsch. 1973. Immunochemical studies of the O-antigens of Vibrio cholerae: partial characterization of an acid-labile antigenic determinant. AJEBAK 51:229235.
89. Robbins, J. B.,, K. Kenny,, and E. Suter. 1965. The isolation and biological activities of rabbit gamma-M and gamma-G anti-Salmonella typhimurium antibodies. J. Exp. Med. 122:385402.
90. Robbins, J. B.,, J. C. Parke,, R. Schneerson,, and J. K. Whisnant. 1973. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7:103110.
91. Robbins, J. B.,, and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. 7. Infect. Dis. 161:821832.
92. Robbins, J. B.,, R. Schneerson,, M. P. Glode,, W. E Vann,, M. S. Schiffer,, T.-Y. Liu,, J.C. Parke, Jr.,, and C. Huntley. 1975. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J. Allergy Clin. Immunol. 56:141151.
93. Sack, D. A.,, J. D. Clemens,, S. Huda,, J. R. Harris,, M. R. Khan,, J. Chakraborty,, M. Yunis,, J. Gomes,, O. Siddique,, F. Ahmed,, B. A. Kay,, F. P. L. van Loon,, M. R. Rao,, A.-M. Svennerholm,, and J. Holmgren. 1991. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 164:407411.
94. Santosham, M.,, R. Reid,, D. M. Ambrosino,, M. C. Wolf,, J. Almeido-Hill,, C. Priehs,, K. M. Aspery,, S. Garrett,, L. Croll,, S. Foster,, G. Burge,, P. Page,, B. Zacher,, R. Moxon,, and G. Siber. 1987. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med. 317:923929.
95. Sato, H.,, Y. Sato,, and I. Ohishi. 1987. Effect of monoclonal antibody to pertussis toxin on toxin activity. Infect. Immun. 55:909915.
96. Schneerson, R.,, J. B. Robbins,, C.-Y. Chu,, A. Sutton,, W. Vann,, J. C. Vickers,, W. T. London,, B. Curfman,, M. C. Hardegree,, J. Shiloach,, and S. C. Rastogi. 1984. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A polysaccharide-protein conjugates. Infect. Immun. 45:582591.
97. Schwartzer, T. A.,, D. V. Alcid,, V. Numsuwan,, and D. J. Gocke. 1988. Characterization of the human antibody response to an Escherichia coli OHl:B4 and J5 vaccine. J. Infect. Dis. 158:11351136.
98. Sommer, A.,, and W. H. Mosley. 1973. Ineffectiveness of cholera vaccination as an epidemic control measure. Lancet i:12321235.
99. Svennerholm, A.-M.,, and J. Holmgren. 1976. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun. 13:735740.
100. Szu, S. C.,, X. Li,, R. Schneerson,, J. H. Vickers,, D. Bryla,, and J. B. Robbins. 1989. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun. 57: 38233827.
101. Szu, S. C.,, R. Schneerson,, and J. B. Robbins. 1986. Rabbit antibodies to the cell wall poly saccharide of Streptococcus pneumoniae fail to protect mice from lethal infection with encapsulated pneumococci. Infect. Immun. 54:448455.
102. Tsai, C.-M. 1986. The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis. J. Biol. Stand. 14:2533.
103. Valdespino Gomez, J. L. Unpublished data.
104. Waldman, R. H.,, Z. Benzie,, B. C. Deb,, R. Sakazaki,, K. Tamura,, S. Mukerjee,, and R. Gguly. 1972. Cholera immunology. II. Serum and intestinal antibody response after naturally occurring cholera. J. Infect. Dis. 126:401407.
105. Watanabe, Y.,, and W. F. Verwey,. 1965. The preparation and properties of a purified mouse-protective lipopolysaccharide form the Ogawa subtype of the El Tor variety of Vibrio cholerae, p. 253259. O. A. Bushell, and C. S. Brookhyer (ed.), Proceedings of the Cholera Research Symposium. Public Health Service publication no. 1328. U.S. Government Printing Office, Washington, D.C.
106. Watanabe, Y.,, and W. F. Verwey. 1965. Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor Vibrio (Ogawa subtype). Bull. W.H.O. 32:809821.
107. Watson, D. C.,, J. B. Robbins,, and S. C. Szu. 1992. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60:46794686.
108. Wernet, P.,, H. Breu,, J. Knop,, and D. Rowley. 1971. Antibacterial action of specific IgA and transport of IgM, IgA and IgG form serum into the small intestine. J. Infect. Dis. 124:223226.
109. Westphal, O.,, and K. Jann. 1965. Bacterial lipopolysaccharide extraction with phenol:water and further application of the procedure. Methods Carbohydr. Chem. 5:8391.
110. Winner, L., III,, J. Mack,, R. Weltzin,, J. J. Mekalanos,, J.-P. Kraehenbuhl,, and M. R. Neutra. 1991. New model of analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect. Immun. 59:977982.
111. Woodward, W. E. 1971. Cholera reinfection in man. J. Infect. Dis. 123:6166.
112. Woodward, W. E.,, W. H. Mosley,, and W. W. McCormack. 1970. The spectrum of cholera in rural East Pakistan. J. Infect. Dis. Suppl. 121:S10S16.

Tables

Generic image for table
Table 1

Serum LPS antibodies elicited in mice by three injections of DeA-LPS-CT, LPS, or cellular cholera vaccines

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25
Generic image for table
Table 2

Vibriocidal antibody titers of pooled sera from mice immunized with cholera conjugates, LPS, or cellular vaccines

Citation: Szu S, Robbins J, Gupta R. 1994. Induction of Serum Vibriocidal Antibodies by O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera, p 381-394. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch25

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error